Simplex Trading’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.63M | Sell |
127,100
-263,100
| -67% | -$3.35M | ﹤0.01% | 2012 |
|
|
2025
Q4 | $3.51M | Buy |
390,200
+145,900
| +60% | +$2.01M | ﹤0.01% | 1543 |
|
|
2025
Q3 | $4.22M | Buy |
244,300
+120,400
| +97% | +$1.48M | ﹤0.01% | 1627 |
|
|
2025
Q2 | $1.16M | Sell |
123,900
-39,300
| -24% | -$323K | ﹤0.01% | 2630 |
|
|
2025
Q1 | $1.16M | Buy |
163,200
+56,100
| +52% | +$567K | ﹤0.01% | 2559 |
|
|
2024
Q4 | $1.25M | Buy |
107,100
+3,500
| +3% | +$54.6K | ﹤0.01% | 2631 |
|
|
2024
Q3 | $2.13M | Buy |
103,600
+31,800
| +44% | +$733K | ﹤0.01% | 2220 |
|
|
2024
Q2 | $1.61M | Sell |
71,800
-51,400
| -42% | -$1.22M | ﹤0.01% | 2416 |
|
|
2024
Q1 | $3.39M | Buy |
123,200
+82,200
| +200% | +$2.28M | ﹤0.01% | 1927 |
|
|
2023
Q4 | $1.25M | Buy |
41,000
+38,600
| +1,608% | +$1.11M | ﹤0.01% | 2807 |
|
|
2023
Q3 | $75K | Sell |
2,400
-62,500
| -96% | -$2.42M | ﹤0.01% | 5392 |
|
|
2023
Q2 | $2.65M | Buy |
64,900
+49,800
| +330% | +$2.02M | ﹤0.01% | 1743 |
|
|
2023
Q1 | $562K | Buy |
15,100
+12,600
| +504% | +$494K | ﹤0.01% | 3143 |
|
|
2022
Q4 | $87K | Sell |
2,500
-11,300
| -82% | -$537K | ﹤0.01% | 5248 |
|
|
2022
Q3 | $772K | Sell |
13,800
-28,700
| -68% | -$1.78M | ﹤0.01% | 2963 |
|
|
2022
Q2 | $2.2M | Buy |
42,500
+36,400
| +597% | +$1.85M | ﹤0.01% | 1774 |
|
|
2022
Q1 | $443K | Sell |
6,100
-1,400
| -19% | -$119K | ﹤0.01% | 3986 |
|
|
2021
Q4 | $886K | Sell |
7,500
-67,700
| -90% | -$8.48M | ﹤0.01% | 3030 |
|
|
2021
Q3 | $12.9M | Buy |
75,200
+8,200
| +12% | +$1.24M | 0.01% | 615 |
|
|
2021
Q2 | $10.8M | Buy |
67,000
+66,590
| +16,241% | +$5.19M | 0.01% | 682 |
|
|
2021
Q1 | $3.29M | Sell |
410
-63
| -13% | -$4.23K | 0.01% | 1147 |
|
|
2020
Q4 | $2.57M | Buy |
473
+365
| +338% | +$13.3K | ﹤0.01% | 1512 |
|
|
2020
Q3 | $214K | Sell |
108
-86
| -44% | -$1.79K | ﹤0.01% | 4026 |
|
|
2020
Q2 | $407K | Sell |
194
-190
| -49% | -$3.23K | ﹤0.01% | 3162 |
|
|
2020
Q1 | $469K | Sell |
384
-153
| -28% | -$2.06K | ﹤0.01% | 2662 |
|
|
2019
Q4 | $787K | Buy |
537
+478
| +810% | +$6.65K | ﹤0.01% | 2307 |
|
|
2019
Q3 | $78K | Sell |
59
-105
| -64% | -$1.67K | ﹤0.01% | 4584 |
|
|
2019
Q2 | $268K | Sell |
164
-156
| -49% | -$2.45K | ﹤0.01% | 3189 |
|
|
2019
Q1 | $546K | Buy |
320
+310
| +3,100% | +$4.62K | ﹤0.01% | 2566 |
|
|
2018
Q4 | $13K | Sell |
10
-261
| -96% | -$4.85K | ﹤0.01% | 5674 |
|
|
2018
Q3 | $775K | Sell |
271
-46
| -15% | -$1.34K | ﹤0.01% | 2141 |
|
|
2018
Q2 | $867K | Buy |
317
+71
| +29% | +$1.72K | ﹤0.01% | 1924 |
|
|
2018
Q1 | $199K | Sell |
246
-26
| -10% | -$639 | 0.01% | 1239 |
|
|
2017
Q4 | $143K | Buy |
272
+157
| +137% | +$3.63K | 0.01% | 1529 |
|
|
2017
Q3 | $15K | Buy |
115
+71
| +161% | +$1.34K | ﹤0.01% | 3430 |
|
|
2017
Q2 | $2K | Buy |
44
+34
| +340% | +$475 | ﹤0.01% | 5300 |
|
|
2017
Q1 | $1K | Buy |
+10
| New | +$134 | ﹤0.01% | 5724 |
|
Other funds holding NTLA
AIM
VPM
VCM
RP
Simplex Trading's NTLA Position: Q4 2025 in Review
Simplex Trading sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 147,300 shares — an estimated $2.03M sold.
Simplex Trading first reported a position in NTLA in Q1 2017 and held it in 27 quarters. The position peaked at $2.54M in Q3 2025. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.
- Simplex Trading reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
- Simplex Trading sold 147,300 Intellia Therapeutics shares in Q4 2025, an estimated $2.03M.
- Simplex Trading first reported a position in Intellia Therapeutics in Q1 2017 and held it in 27 quarters.
- Simplex Trading's Intellia Therapeutics position peaked at $2.54M in Q3 2025.
- 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.
Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.